Neuropsychiatric Symptoms in Alzheimer’s Disease Linked to Amyloid and Heat Shock Proteins

Neuropsychiatric symptoms—agitation, apathy, depression, and psychosis-like disturbances—are among the most common and distressing features of Alzheimer’s disease, and they may accelerate cognitive decline. A new cross-sectional study published in BMC Medicine analyzed 713 participants from the Alzheimer’s Disease Neuroimaging Initiative who had neuropsychiatric symptom assessments, cerebrospinal fluid amyloid-β42 measurements, SomaScan 7K proteomics, and cognition data, in an effort to trace the molecular pathways connecting behavioral symptoms to the disease’s hallmark amyloid pathology.

The researchers assessed symptoms using the Neuropsychiatric Inventory Questionnaire and grouped them into four subsyndromes: hyperactivity, psychosis, affective symptoms, and apathy. Regression and mediation analyses showed that a higher overall neuropsychiatric burden, as well as the hyperactivity, affective, and apathy subsyndromes, was cross-sectionally associated with lower cerebrospinal fluid levels of amyloid-β42, a marker of amyloid pathology. Reduced amyloid-β42 partially mediated the association between neuropsychiatric symptoms and cognition, suggesting the protein changes could represent one molecular route through which behavioral symptoms relate to cognitive impairment.

To probe the protein landscape, the team applied weighted gene co-expression network analysis, which identified three protein modules associated with neuropsychiatric symptoms. The largest and most phenotypically relevant module, labeled MEyellow, was enriched in biological processes including protein folding, ubiquitination, stress responses, and immune regulation, and its constituent proteins were expressed predominantly in neurons.

Protein-protein interaction network analysis then revealed a hub cluster centered on two protein families: the heat shock proteins and the ubiquitin-conjugating enzymes E2. This hub cluster significantly mediated the association between neuropsychiatric symptoms and reduced cerebrospinal fluid amyloid-β42.

The researchers also used Mendelian randomization, a genetic approach that can support causal inference, to validate the findings. This analysis supported causal effects of the heat shock protein HSPB1 on hyperactivity and of HSPA1A on apathy, pointing to specific chaperone proteins as candidate drivers of particular symptom clusters.

The authors conclude that the findings suggest a potential relationship among neuropsychiatric symptoms, reduced cerebrospinal fluid amyloid-β42, and cognitive impairment, and they implicate the heat shock protein family as a candidate therapeutic target for early intervention in Alzheimer’s disease—pending further validation. Because the study is cross-sectional, it captures associations at a single time point and cannot establish that symptoms drive amyloid changes or vice versa; the mediation results indicate partial, not complete, pathways. The participants were drawn from a single research cohort, and the early-access version of the article is subject to further edits before the final version of record.

Even with those limitations, the convergence of independent analytical approaches—regression, network analysis, and genetic instrumentation—on the same chaperone and protein-degradation machinery offers a testable molecular hypothesis for a set of symptoms that has long been treated as clinically important but mechanistically opaque. If validated in longitudinal and independent cohorts, heat shock proteins such as HSPB1 and HSPA1A could become targets for interventions aimed at patients experiencing neuropsychiatric symptoms early in the disease course.

Subject of Research: Cross-sectional associations between neuropsychiatric symptoms, cerebrospinal fluid amyloid pathology, and heat shock protein signatures in Alzheimer's disease

Article Title: Associations between neuropsychiatric symptoms and cerebrospinal fluid amyloid pathology, and convergent proteomic signatures in Alzheimer’s disease

Article References: Wang, Y.-Y., Zhu, H.-Y., Miao, W., Wang, Y.-H., Song, X.-H., Qin, J.-J., Wang, Z.-X., Sun, Z.-W., Zhou, X., Yu, X.-F., Zhao, J.-H., Alzheimer’s Disease Neuroimaging Initiative, & Zhu, X.-Q. (2026). Associations between neuropsychiatric symptoms and cerebrospinal fluid amyloid pathology, and convergent proteomic signatures in Alzheimer’s disease. BMC Medicine. https://doi.org/10.1186/s12916-026-05364-z

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05364-z

Keywords: Alzheimer's disease, neuropsychiatric symptoms, amyloid-β42, cerebrospinal fluid, proteomics, heat shock proteins, HSPB1, HSPA1A, Mendelian randomization, ADNI, cognitive decline, protein folding